Chronic mirabegron treatment increases human brown fat, HDL cholesterol, and insulin sensitivity

BACKGROUND: Mirabegron is a β3-adrenergic receptor (β3-AR) agonist approved only for the treatment of overactive bladder. Encouraging preclinical results suggest that β3-AR agonists could also improve obesity-related metabolic disease by increasing brown adipose tissue (BAT) thermogenesis, white adi...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Clin Invest
Главные авторы: O’Mara, Alana E., Johnson, James W., Linderman, Joyce D., Brychta, Robert J., McGehee, Suzanne, Fletcher, Laura A., Fink, Yael A., Kapuria, Devika, Cassimatis, Thomas M., Kelsey, Nathan, Cero, Cheryl, Sater, Zahraa Abdul, Piccinini, Francesca, Baskin, Alison S., Leitner, Brooks P., Cai, Hongyi, Millo, Corina M., Dieckmann, William, Walter, Mary, Javitt, Norman B., Rotman, Yaron, Walter, Peter J., Ader, Marilyn, Bergman, Richard N., Herscovitch, Peter, Chen, Kong Y., Cypess, Aaron M.
Формат: Artigo
Язык:Inglês
Опубликовано: American Society for Clinical Investigation 2020
Предметы:
Clinical Medicine
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7190915/
https://ncbi.nlm.nih.gov/pubmed/31961826
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI131126
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы